Biology subjects

Legeai-Mallet, L.

Publications and source records attributed to Legeai-Mallet, L..

5 recordsLinked to original sources

bioRxiv2026

Mitochondrial dysfunction plays a key role in premature musculoskeletal aging in hypochondroplasia mouse model

Hypochondroplasia (HCH) is a mild form of chondrodysplasia, caused by variants in fibroblast growth factor receptor 3 (FGFR3). Today, the biological mechanism underlying musculoskeletal aging in HCH remains largely unknown. In this study, we show that Hch mice exhibit phenotypic traits of bone fragility and accelerated age-dependent articular cartilage and subchondral bone changes. Hch mice also presented decreased muscle strength and reduction in muscle fibers size. Furthermore, proteomics analyses of the cortical bone revealed that Hch mice follow a different aging trajectory than control. FGFR3 mutation leads to a premature boost of the mitochondrial processes forcing the mutant to reach a physiological state much earlier than the control. Together, these findings demonstrate that aging in Hch mice is accompanied by bone fragility and osteoarthritis-like changes. Proteomics analyses highlighted the key role for mitochondria in the cortical bone of Hch mice, providing insight into the mechanisms underlying premature aging in HCH.

genetics↗

bioRxiv2026

Rewiring Fibroblast-Muscle Axis Drives Progressive Pathology in Bethlem Myopathy

Collagen VI-related myopathies, including Bethlem myopathy (BM), are progressive muscle disorders, but the mechanisms driving age-dependent disease progression remain poorly understood. Here, we used a zebrafish BM model carrying an exon-skipping mutation that generates a shorter collagen VI 1 chain and disrupts supramolecular assembly, recapitulating key features of the human disease. We further demonstrated that this model reproduces disease progression, with worsening muscle wasting, increased myofiber size variability, and age-associated skeletal deformities consistent with secondary consequences of muscle dysfunction rather than intrinsic bone defects. Single-nucleus RNA sequencing of trunk skeletal muscle revealed an early shift in cellular composition, with reduced myonuclei and increased fibroblast abundance, indicative of disease-associated aging. Myonuclei activated stress and quality control pathways, including autophagy and mitophagy, along with metabolic rewiring. In contrast, fibroblasts displayed early translational activation followed by progressive proteostatic and endoplasmic reticulum stress. At later stages, fibroblasts adopted a pro-fibrotic state, driving extracellular matrix remodeling and enhanced muscle-fibroblast communication. Consistently, analyses at the protein level confirmed early intracellular retention of the mutant protein, along with increased extracellular matrix deposition and fibrotic tissue formation in BM muscle. Among the three tested drugs targeting ER-stress and protein degradation, only TUDCA significantly ameliorated collagen VI deposition in the extracellular space in larvae. These findings identify fibroblasts as key drivers of disease progression and potential therapeutic targets.

developmental biology↗

bioRxiv2025

Cranial suture integrity is maintained by Fgfr3 in zebrafish

Cranial suture formation is a dynamic process requiring precise cellular and molecular coordination to regulate bone growth and suture homeostasis. Despite the recognized role of Fibroblast Growth Factor Receptor 3 (FGFR3) in this process and its association with Muenke syndrome, one of the most common syndromic craniosynostoses, its precise function remains undefined. Through analyses of cranial suture formation and maintenance in a fgfr3 LoF zebrafish model displaying abnormal suture morphology, we demonstrate for the first time that Fgfr3 plays a pleiotropic role during these events. Transmission electron microscopy and second harmonic generation imaging revealed that Fgfr3 is involved in the proper organization of the collagen network within the suture. By employing specific transgenic reporter lines and studying gene expression of suture mesenchymal stem cell markers via RNAscope in situ hybridization, we show that Fgfr3 is crucial for regulating osteogenesis within the suture. Specifically, Fgfr3 limits the number of osteoprogenitors at the osteogenic front and promotes osteoblast maturation at the suture edge. Finally, our results reveal that Fgfr3-mediated regulation of osteogenesis involves cross-talk between FGF, canonical Wnt, and potentially BMP signaling pathways. In conclusion, these data position Fgfr3 as a central regulator of cranial suture formation and open new perspectives for understanding suture homeostasis and FGFR3-related craniosynostoses.

developmental biology↗

bioRxiv2020

The phosphatase inhibitor LB-100 acts synergistically with the NPR2 agonist BMN-111 to improve bone growth

Activating mutations in fibroblast growth factor receptor 3 (FGFR3) and inactivating mutations in the natriuretic peptide receptor 2 (NPR2) guanylyl cyclase both result in decreased production of cyclic GMP (cGMP) in chondrocytes and severe short stature, causing achondroplasia (ACH) and acrosomelic dysplasia type Maroteaux, respectively. Previously we showed that an NPR2 agonist BMN-111 (vosoritide) increases bone growth in mice mimicking ACH (Fgfr3Y367C/+), and that in control growth plate chondrocytes, FGFR3 signaling decreases NPR2 activity by dephosphorylating the NPR2 protein. Here we tested whether a phosphatase inhibitor (LB-100) could enhance bone growth in ACH. In ex vivo imaging experiments using a FRET sensor to measure cGMP production in chondrocytes of living tibias from newborn mice, LB-100 counteracts the FGF-induced dephosphorylation and inactivation of NPR2. In ex vivo experiments with Fgfr3Y367C/+ mice, LB-100 in combination with BMN-111 increases the rate of femur growth by [~]25% vs BMN-111 alone, restores chondrocyte terminal differentiation, increases the proliferative growth plate area of the femur, and reduces the activity of the MAP kinase pathway. Our results provide a proof of concept that a phosphatase inhibitor could be used together with an NPR2 agonist to enhance cGMP production as a therapy for ACH. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=193 HEIGHT=200 SRC="FIGDIR/small/288589v1_ufig1.gif" ALT="Figure 1"> View larger version (21K): org.highwire.dtl.DTLVardef@1d0f5d3org.highwire.dtl.DTLVardef@1bb0724org.highwire.dtl.DTLVardef@1d206d1org.highwire.dtl.DTLVardef@1bd9ad7_HPS_FORMAT_FIGEXP M_FIG C_FIG

developmental biology↗

bioRxiv2020

FGFR3 is a positive regulator of osteoblast expansion and differentiation during zebrafish skull vault development

Gain- or loss-of-function mutations in fibroblast growth factor receptor 3 (FGFR3) result in cranial vault defects - highlighting the proteins role in membranous ossification. Zebrafish express high levels of fgfr3 during skull development; in order to study FGFR3s role in cranial vault development, we generated the first fgfr3 loss-of-function zebrafish (fgfr3lof/lof). The mutant fish exhibited major changes in the craniofacial skeleton, with a lack of sutures, abnormal frontal and parietal bones, and the presence of ectopic bones. Integrated analyses (in vivo imaging, and single-cell RNA sequencing of the osteoblast lineage) of zebrafish fgfr3lof/lof revealed a delay in osteoblast expansion and differentiation, together with changes in the extracellular matrix. These findings demonstrate that fgfr3 is a positive regulator of osteogenesis. We hypothesize that changes in the extracellular matrix within growing bone impair cell-cell communication, mineralization, and new osteoblast recruitment.

developmental biology↗